Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2024 an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer, under the terms of the 2022 Employment Inducement Award Plan, a...
Marathon Digital Holdings Announces Bitcoin Production and Mining Operation Updates for April 2024 - Average Operational Hash Rate Increases 15% M/M to 21.1 EH/s - Increased BTC Holdings to 17,631 BTC; Total Cash and BTC of $1.6 B as of April 30, 2024 - Increased End of Year 2024 Total Installed Hash Rate Guidance to 50 EH/s, Confirmed and Fully Funded Fort Lauderdale, FL, May 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ) ("Marathon" or the "Company"), one of the world’s largest publicly traded Bitcoin miners and a leader in supporting and securing the Bitcoin ecosystem, ...
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, May 9, 2024...
Sportsman’s Warehouse Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WEST JORDAN, Utah, May 02, 2024 (GLOBE NEWSWIRE) -- Sportsman’s Warehouse Holdings, Inc. (“Sportsman’s Warehouse” or the “Company”) (Nasdaq: SPWH) announced today that, effective as of May 1, 2024, the Compensation Committee (the “Committee”) of the Company’s Board of Directors granted an inducement award consisting of 124,610 time-based restricted stock units (“RSUs”) to Paul Stone, the Company’s chief executive officer. The award was a signing bonus granted as an inducement material to Mr....
Blink Charging Selected as Official Electric Vehicle Charger and Network Services Provider for State of New York Blink to provide expanded charging infrastructure and support a more sustainable future for the state. Bowie, Md., May 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: BLNK) (“Blink” or the “Company”), a leading global manufacturer, owner, operator and provider of electric vehicle (EV) charging equipment and services, has announced it has secured a contract as an official EV charging provider for the state of New York. The agreement sets the stage for Blink Charging and New York to ...
CalAmp Enhances School Bus Solutions Suite with Dispatch Monitor New Application Ensures Route Coverage and Improves Driver Efficiency IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CalAmp (Nasdaq: CAMP), a connected intelligence company helping people and organizations improve operational performance with a data-driven solutions ecosystem, proudly announces the launch of Dispatch Monitor. This innovative application seamlessly integrates with the CalAmp K-12 suite of application solutions, fortifying CalAmp's commitment to improving school bus fleet management. Dispatch Monitor prov...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2024 and raised its Adjusted(3) diluted EPS guidance while maintaining all other components of its 2024 financial guidance(6). The first-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at . EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “We delivered strong performance in our non-COVID product portfolio in the first quarter of 2024, including...
NEW YORK & COPENHAGEN, Denmark--(BUSINESS WIRE)-- (NYSE: PFE) and (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. "Recurrent or metastatic cervical cancer is a particularly devastating and mostly incurable disease, and patients are in need of survival-extending treatment options,” said Chris Boshoff, M.D., Ph.D., Chief...
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class Pharmacokinetic data show no clinically significant difference in exposure between fed and fasted dosing Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place May 31 to June 4 in Chicago. More than 50 abstracts, including 11 oral presentations, will be presented from Pfizer’s broadened portfolio of approved and pipeline therapies across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies. “We are excited to participate in our first ASCO A...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test. BEQVEZ is a one-time treatment that is designed to ena...
Marathon Digital Holdings Increases 2024 Hash Rate Target to 50 Exahash New 50 EH/s Target Represents Approximately 100% Growth in Hash Rate during Fiscal Year 2024 Fort Lauderdale, FL, April 25, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:) ("Marathon" or "Company"), one of the world’s largest publicly traded Bitcoin miners and a leader in supporting and securing the Bitcoin ecosystem, today announced that the Company is increasing its hash rate target for fiscal year 2024 from 35-37 EH/s to 50 EH/s. Marathon began 2024 with approximately 24.7 EH/s energized and had been planning to grow its...
BRT Apartments Corp. Announces Filing Date for First Quarter 2024 Earnings Results GREAT NECK, N. Y., April 25, 2024 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE:BRT), a real estate investment trust that owns, operates, and, to a lesser extent, holds interests in joint ventures that own multi-family properties, today announced it intends to file its Form 10-Q for the quarter ended March 31, 2024 with the Securities and Exchange Commission on or about May 9, 2024. The Company does not intend to conduct an earnings call to discuss the results. BRT is a real estate investment trust that ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.